AiCuris CEO Holger Zimmermann talks to Mike Ward, global director of content for Informa Pharma Intelligence, about the company's journey to becoming a clinical biotech company since being spun out of Bayer AG as a small research group a decade ago.
AiCuris GMBH & Co. KG CEO Holger Zimmermann highlights AiCuris's anti-infectives development pipeline, the next big goals for the company and how new partners might fit into its plans.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.
Lead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study.
